Does yoga regulate the miRNA levels in persons with epilepsy?

Elucidating the efficacy of yoga-meditation and its associated epigenetic modulation in persons with temporal plus and temporal lobe epilepsy

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/02/031455

Enrollment

120

Registered

2021-02-22

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset Health Condition 2: G402- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures Health Condition 3: G401- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures Health Condition 4: G408- Other epilepsy and recurrent seizures

Interventions

Intervention1: Integrated yoga-meditation module: The treatment would consist of 7 supervised group sessions lasting about 45-60 minutes conducted over a period of 12 weeks. The protocol for the medit

Eligibility

Inclusion criteria

Inclusion criteria: a) Consenting b) Persons diagnosed as having active epilepsy. c) Age greater than 18 years, but less than 60 years. d) Patients with clinically diagnosed temporal lobe or temporal plus epilepsy e) Patients who have had at least one seizure in the past one month

Exclusion criteria

Exclusion criteria: a) Non-Consenting b) Actively or previously practicing meditation/ yoga for a period of three months or longer

Design outcomes

Primary

Measure	Time frame
To assess the changes in levels of microRNAs implicated in epilepsy after a 12 week yoga-meditation based intervention as compared to a sham yoga protocolTimepoint: baseline, 8 weeks, 12 weeks	—

Secondary

Measure	Time frame
To evaluate the efficacy of these intervention modules in decreasing neuro-psychological comorbidity as assessed by Generalized Anxiety Disorder Scale-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9) and Quality of Life (QoLIE-10)Timepoint: Baseline, 12 weeks, 6 months;To evaluate the efficacy of these interventions in improving electroencephalographic, namely spectral intensity as recorded by a high-density (128 channel) EEG.Timepoint: Baseline, 12 weeks;To evaluate the efficacy of these interventions in reducing the seizure frequency and severity as recorded on a seizure diaryTimepoint: Baseline, 8 weeks, 12 weeks, 6 months	—

Measure

Time frame

To evaluate the efficacy of these intervention modules in decreasing neuro-psychological comorbidity as assessed by Generalized Anxiety Disorder Scale-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9) and Quality of Life (QoLIE-10)Timepoint: Baseline, 12 weeks, 6 months;To evaluate the efficacy of these interventions in improving electroencephalographic, namely spectral intensity as recorded by a high-density (128 channel) EEG.Timepoint: Baseline, 12 weeks;To evaluate the efficacy of these interventions in reducing the seizure frequency and severity as recorded on a seizure diaryTimepoint: Baseline, 8 weeks, 12 weeks, 6 months

—

Countries

India

Contacts

Public ContactDr Manjari Tripathi

AIIMS, Delhi

mtripathiaiims@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026